Filing Flows › Starling Oncology (STLN) › How it makes money
How Starling Oncology (STLN) makes money
Starling Oncology (STLN) made $169M of revenue in the third quarter 2026 (Q3 2026), +24% from a year earlier. Specialty Pharmacy brought in $109M (65%); Patient services brought in $60.0M (35%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Specialty Pharmacy | $109M | 64.6% | +11% | +44% |
| Patient services | $60.0M | 35.4% | +2% | -0.3% |
| ↳ FFS revenue | $31.3M | 18.5% | +1% | -21% |
| ↳ Capitated revenue | $28.7M | 17.0% | +3% | +40% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $169M | 100.0% |
| Operating cash flow | $10.1M | 6.0% |
| Free cash flow | $8.9M | 5.2% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $170M | +24% |
| Q2 2026 | $161M | +35% |
| Q1 2026 | $147M | +41% |
| Q4 2025 | $142M | +42% |
| Q3 2025 | $137M | +37% |
| Q2 2025 | $120M | +22% |
| Q1 2025 | $104M | +10% |
From Starling Oncology's 10-Q filed Nov 6, 2026 (on EDGAR).
Questions
How does Starling Oncology make money?
Starling Oncology (STLN) made $169M of revenue in the third quarter 2026 (Q3 2026), +24% from a year earlier. Specialty Pharmacy brought in $109M (65%); Patient services brought in $60.0M (35%).
What is Starling Oncology's biggest business?
Specialty Pharmacy: $109M in the third quarter 2026, 65% of revenue, +44% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.